Alkermes Plc Reports Third Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Alkermes (ALKS) PT Lowered to $47 at Credit Suisse
October 24, 2018 8:54 AM EDTCredit Suisse analyst Vamil Divan lowered the price target on Alkermes (NASDAQ: ALKS) to $47.00 (from $51.00) while maintaining an Outperform rating following Q3.
Divan modestly reduces their sales estimates for Vivitrol and Aristada and also increase some of their expense assumptions... More
Alkermes (ALKS) Tops Q3 EPS by 15c, Revenues Beat; Raises FY18 EPS Guidance
October 23, 2018 7:05 AM EDTAlkermes (NASDAQ: ALKS) reported Q3 EPS of $0.07, $0.15 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $248.7 million versus the consensus estimate of $236.7 million.
"Our solid results in the quarter were in-line with expectations, driven by the growth of our proprietary commercial products, the continued strength of our royalty and manufacturing business, and the important investments we are making in our late-stage pipeline and commercial... More
